📚 Muhammet Ali Kaplan Akademik Yayın Listesi 

Makaleler, en yeni olandan en eskiye doğru (kronolojik) sıralanmıştır. Tekrarlanan girişler (farklı yayın numaralarına sahip aynı DOI'ler) birleştirilerek tek bir giriş halinde sunulmuştur.

2025 Yılı (5 Makale)

  1. Akin Telli T, Tatlı AM, Alan O, Yıldıran Keskin G, Karadurmuş N, Karakaya S, Kaplan MA, Açıkgöz Ö, Bilici A, Eylemer Mocan E, Demirkazık A, Kahraman S, Şendur MAN, Doğan M, Topalgökçeli SM, Er Ö, Ünsal O, Yazıcı O, Özcan E, Kargı A, Gürbüz M, Selçukbiricik F, Şakalar T, Gürsoy P, Bilgin B, Selvi O, Karadağ İ, Eren ÖO, Bayram E, Sümbül AT, Keskin S, Öztürk A, Topçu S, Özen M, Kılıçkap S, Yumuk PF. Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group 2025. Clinical Lung Cancer. DOI: 10.1016/j.cllc.2025.07.015.
  2. Bozcuk HŞ, Sert L, Kaplan MA, Tatlı AM, Karaca M, Muğlu H, Bilici A, Kılıçtaş BŞ, Artaç M, Erel P, Yumuk PF, Bilgin B, Şendur MAN, Kılıçkap S, Taban H, Ballı S, Demirkazık A, Akdağ F, Hacıbekiroğlu İ, Güzel HG, Koçer M, Gürsoy P, Köylü B, Selçukbiricik F, Karakaya G, Alemdar MS. Enhancing Treatment Decisions for Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations: A Reinforcement Learning Approach. Cancers. 2025;17(2):233. DOI: 10.3390/cancers17020233.
  3. Kalkan Z, Ebinç S, Arcagök M, Bilici A, Yıldız Ö, Kılıçkap S, Güven DC, Tatlı AM, Sümbül AT, Mandel NM, Ateş Ö, Bardakçı M, Karakaya S, Kaplan MA. Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study. Medicina. 2025;61(4):638. DOI: 10.3390/medicina61040638.
  4. Şendur MAN, Karadurmuş N, Çiçin İ, Gümüş M, Demirci U, Özyılkan Ö, Kaplan MA, Sezgin GS, Özdemir F, Arslan Ç, vd. Evaluation of implementation of evolving practice patterns in the first-line treatment of patients with metastatic non-small cell lung cancer in Turkiye (ESTIMATE): a national, multicenter, retrospective, real-world evidence study. Future Oncology. 2025.
  5. Urakçı Z, Oruç Z, Kömek H, Ebinç S, Pirinççi E, Kalkan Z, Taşdemir B, Kaplan MA, Küçüköner M, Işıkdoğan A. Comparison of inflammatory indices in patients with metastatic non-small cell lung cancer. Revista da Associação Médica Brasileira. 2025;71(4):e20240411. DOI: 10.1590/1806-9282.20240411.

2024 Yılı (8 Makale)

  1. Kahraman S, Karakaya S, Kaplan MA, Sezgin GS, Öztürk A, Sucuoğlu İşleyen Z, Hamdard J, Yıldırım S, Doğan T, Işık S, Çelebi A, vd. Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases. Scientific Reports. 2024;14(1):21711.
  2. Karadurmuş N, Kaplan MA, Şendur MAN, Ürün Y, Demirci U, Karaca SB, Göktaş AS, Aykan MB, Bilici A, Sezer A, vd. Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye: a retrospective multicenter non-interventional registry study. Current Medical Research and Opinion. 2024;40(8):1201-1208. DOI: 10.1080/03007995.2024.2359026.
  3. Köstek O, Demirel A, Hacıoğlu MB, Taştekin D, Karabulut S, Gündoğdu A, Sever N, Ayhan M, Çelebi A, Majidova N, vd. The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing. Journal of Chemotherapy. 2024.
  4. Özbay MF, Harputluoğlu H, Karaca M, Tekin Ö, Şendur MAN, Kaplan MA, Şahin B, Geredeli Ç, Teker F, Tural D, Saǧlam S, Çil T, Bilici A, Erol C, Kalkan Z, Bayram E, Selvi O, Gültürk İ, Sezgin GS, Tatlı AM. Sequential Use of Sorafenib and Regorafenib in Hepatocellular Cancer Recurrence After Liver Transplantation: Treatment Strategies and Outcomes. Cancers. 2024;16(2):345.
  5. Urakçı Z, Ebinç S, Oruç Z, Kalkan Z, Kaplan MA, Küçüköner M, Işıkdoğan A. Causes of liver test abnormalities in newly diagnosed cancer patients and the investigation of etiological factors. Postgraduate Medicine. 2024;136(3):284-289. DOI: 10.1080/00325481.2024.2316571.
  6. Urakçı Z, Kaplan MA, Oruç Z, Gümüş M, Uncu D, Ebinç S, Özkan M, Geredeli Ç, Elkıran ET, Girgin S. Superiority of Pathologic Lymph Node Ratio over Positive Lymph Node Count in Operated Early-Stage Breast Cancer. Annali Italiani di Chirurgia. 2024. DOI: 10.62713/aic.3319.
  7. Yıldırım HÇ, Bayram E, Güven DC, Erdoğan AP, Öztürk B, Kazaz SN, Çiçin İ, Semiz HS, Sarı M, Akgül ÖF, vd. Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma. Journal of Chemotherapy. 2024.
  8. Yıldırım HÇ, Bayram E, Chalabiyev E, Majidova N, Avcı T, Güzel HG, Kapar C, Uzun M, Perkin P, Akgül F, vd. Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma. Journal of Chemotherapy. 2024.

2023 Yılı (12 Makale)

  1. Bilici A, Ölmez ÖF, Kaplan MA, Çakmak Öksüzoğlu ÖB, Sezer A, Karadurmuş N, Çubukçu E, Şendur MAN, Aksoy S, Erdem D, Başaran G, Tural D, Akbulut H, vd. Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study. Acta Oncologica. 2023;62(5):541-551. DOI: 10.1080/0284186X.2023.2202330.
  2. Bilici A, Koca S, Karaağaç M, Göktaş AS, Eraslan E, Kaplan MA, Ocak B, Sezgin GS, Paydaş S, Akgül F, vd. Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study. Cancer Chemotherapy and Pharmacology. 2023;92(1):47-58. DOI: 10.1007/s00432-023-04766-3.
  3. Ebinç S, Güzel Y, Oruç Z, Kömek H, Kalkan Z, Can C, Taşdemir B, Urakçı Z, Kaplan MA, Küçüköner M, Işıkdoğan A. 18 F-FDG PET/CT parameters for prediction of response to neoadjuvant therapy and prognosis in rectal cancer. Nuclear Medicine Communications. 2023;44(7):594-601. DOI: 10.1097/MNM.0000000000001638.
  4. Ebinç S, Kalkan Z, Oruç Z, Sezgin Y, Urakçı Z, Küçüköner M, Kaplan MA, Işıkdoğan A. Factors influencing the prognosis in Braf wild-type metastatic malignant melanoma and the role of novel inflammation indices. Türkderm-Türk Deri Hastalıkları ve Frengi Arşivi. 2023;57(3):148-156. DOI: 10.4274/turkderm.galenos.2023.52721.
  5. Ebinç S, Oruç Z, Kalkan Z, Karhan O, Urakçı Z, Küçüköner M, Kaplan MA, Işıkdoğan A. Prognostic factors and the prognostic role of inflammation indices in malignant pleural mesothelioma. Turkish Journal of Thoracic and Cardiovascular Surgery. 2023;31(2):166-173. DOI: 10.5606/tgkdc.dergisi.2023.23365.
  6. Ebinç S, Oruç Z, Kalkan Z, Teke F, Onat S, Urakçı Z, Kaplan MA, Küçüköner M, Işıkdoğan A. Neoadjuvant Therapy and Factors Influencing Survival in Locally Advanced Non-Small Cell Lung Cancer. Cureus. 2023;15(1):e33392. DOI: 10.7759/cureus.33392.
  7. Kaplan MA, Şendur MAN, Kayı CA, Fırat P, Göker E, Kılıçkap S, Oyan Uluç B, Öz AB, Özdemir F, Özyiğit G. Established and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Group. Current Problems in Cancer. 2023;47(3):101017. DOI: 10.1016/j.currproblcancer.2023.101017.
  8. Pirinççi E, Oruç Z, Ebinç S, Güzel Y, Kömek H, Küçüköner M, Urakçı Z, Kaplan MA, Taşdemir B, Işıkdoğan A. The relationship between inflammation markers, positron emission tomography/computed tomography parameters and disease prognosis in advanced non-small-cell lung cancer patients. Oncology in Clinical Practice. 2023;19(1):47-52. DOI: 10.5603/ocp.97451.
  9. Urakçı Z, Ebinç S, Tunç S, Kalkan Z, Oruç Z, Küçüköner M, Kaplan MA, Işıkdoğan A. Comparison of Two Chemotherapy Regimens After First-Line Treatment for HER2-Negative Metastatic Gastric Cancer. Cureus. 2023;15(5):e38837. DOI: 10.7759/cureus.38837.
  10. Urakçı Z, Ebinç S, Tunç S, Oruç Z, Küçüköner M, Kaplan MA, Işıkdoğan A. Factors predicting pathological complete response to neoadjuvant chemotherapy in patients diagnosed with non-metastatic muscle invasive urothelial bladder cancer. Northwestern Medical Journal. 2023;5(1):15-20. DOI: 10.54307/NWMJ.2023.41275.
  11. Urakçı Z, Ebinç S, Oruç Z, Kaplan MA, Küçüköner M, Işıkdoğan A. Effectiveness of Current First-Line Treatments and Evaluation of Prognostic Factors Related to Survival in Castration-Resistant Prostate Cancer with Isolated Bone Metastasis. Journal of Oncological Sciences. 2023;9(1):13-19.
  12. Urakçı Z, Ebinç S, Oruç Z, Kalkan Z, Kaplan MA, Küçüköner M, Işıkdoğan A. Efficacy of pemetrexed plus a platinum rechallenge in the treatment of pleural mesothelioma. Oncology in Clinical Practice. 2023;19(1):40-46. DOI: 10.5603/OCP.2023.0014.

2022 Yılı (9 Makale)

  1. Akdeniz N, Kaplan MA, Küçüköner M, Urakçı Z, Laçin Ş, Ceylan EH, Işıkdoğan A. The effect of exercise on disease-free survival and overall survival in patients with breast cancer. Irish Journal of Medical Science. 2022;191(1):411-417. DOI: 10.1007/s11845-021-02785-y.
  2. Bilici A, Uysal M, Menekşe S, Akın S, Yıldız F, Turan M, Sezgin GS, Beypınar İ, Şakalar T, Değirmenci M, Erdem D, Başaran G, Ölmez ÖF, Avcı N, Tural D, Sakin A, Türker S, Demir A, Temiz S, Kaplan MA, Doğan M, Tanrıverdi Ö, Bilgetekin İ, Yeşil Çınkır H, Açıkgöz Ö, Paydaş S, Uslu R, Turhal NS. Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study. Cancer Investigation. 2022;40(2):98-109. DOI: 10.1080/07357907.2021.2017952.
  3. Ebinç S, Oruç Z, Urakçı Z, Kaplan MA, Küçüköner M, Işıkdoğan A. Investigation of Factors Influencing the Prognosis in Prostate Cancer Patients with Isolated Bone Metastasis. Bulletin of Urooncology. 2022;21(3):273-280. DOI: 10.4274/uob.galenos.2022.2022.1.4.
  4. Ebinç S, Oruç Z, Sezgin Y, Karhan O, Bilen E, Yerlikaya H, Kalkan Z, Urakçı Z, Küçüköner M, Kaplan MA, Işıkdoğan A. Factors influencing HER2 discordance in nonmetastatic breast cancer and the role of neoadjuvant therapy. Future Oncology. 2022;18(33):3567-3575. DOI: 10.2217/fon-2022-0198.
  5. Ebinç S, Oruç Z, Urakçı Z, Kalkan Z, Kaplan MA, Küçüköner M, Işıkdoğan A. Evaluation of Factors Predicting the Effectiveness of Regorafenib in the Treatment of Metastatic Colorectal Cancer. The Eurasian Journal of Medicine. 2022;54(3):263-268. DOI: 10.5152/eurasianjmed.2022.21162.
  6. Ebinç S, Kalkan Z, Oruç Z, Urakçı Z, Küçüköner M, Kaplan MA, Işıkdoğan A. Evaluation of the effectiveness and tolerability of sunitinib and pazopanib in the first line treatment of metastatic renal cell carcinoma. Oncology in Clinical Practice. 2022;18(3):144-151. DOI: 10.5603/OCP.2021.0033.
  7. İlhan Y, Tatlı AM, Teker F, Önder AH, Köse F, Geredeli Ç, Karaağaç M, Kaplan MA, İnanç M, Göktaş AS, vd. Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer. International Journal of Gynecological Cancer. 2022;32(2):220-227. DOI: 10.1136/ijgc-2021-003165.
  8. Oruç Z, Akbay A, Kaplan MA, Oruç İ, Küçüköner M, Işıkdoğan A. A Low Body Fat Mass Ratio Predicts Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer. Nutrition and cancer. 2022;74(6):2044-2051. DOI: 10.1080/01635581.2022.2074064.
  9. Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, Talbot T, Monnet I, Hiret S, Bass P, Nowak A, vd. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Annals of Oncology. 2022;33(5):541-551. DOI: 10.1016/j.annonc.2022.01.074.

2021 Yılı (4 Makale)

  1. Akdeniz N, Kaplan MA, Uncu D, İnanç M, Kaya S, Dane F, Küçüköner M, Demirci A, Bilici M, Durnalı A, vd. The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter study. International Journal of Colorectal Disease. 2021;36(5):989-995. DOI: 10.1007/s00384-021-03888-9.
  2. Akdeniz N, Kömek H, Küçüköner M, Kaplan MA, Urakçı Z, Oruç Z, Işıkdoğan A. The role of basal 18F-FDG PET/CT maximum standard uptake value and maximum standard uptake change in predicting pathological response in breast cancer patients receiving neoadjuvant chemotherapy. Nuclear Medicine Communications. 2021;42(11):1196-1201. DOI: 10.1097/MNM.0000000000001332.
  3. Oruç Z, Kaplan MA, Karaağaç M, Özyurt N, Tatlı AM, Kaya AO, Menekşe S, Kut E, Koca S, Sever ÖN, vd. Efficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastases. Future Oncology. 2021;17(15):1889-1901. DOI: 10.2217/fon-2020-1032.
  4. Paydaş S, Laçin Ş, Doğan M, Barışta İ, Yıldız B, Seydaoğlu G, Karadurmuş N, Civriz Bozdağ S, Kaplan MA, Yağcı AM, vd. Easier and more explanatory indices by integrating leukocyte lymphocyte ratio (LLR) and prognostic nutritional index (PNI) to IPS systems in cases with classical Hodgkin lymphoma. Leukemia Research. 2021;103:106586. DOI: 10.1016/j.leukres.2021.106586.

2020 Yılı (2 Makale)

  1. Karaağaç M, Sezgin Y, Karakurt Eryılmaz M, Araz M, Kaplan MA, Artaç M. The real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: A retrospective cross-sectional study of a Turkish cohort. Journal of Oncology Pharmacy Practice. 2020;26(5):1179-1186. DOI: 10.1177/1078155220904138.
  2. Tatlı AM, Urakçı Z, Taştekin D, Koca D, Sezgin GS, Üyetürk Ü, Kaplan MA, Coşkun HŞ. A retrospective evaluation of geriatric patients with gastric cancer receiving systemic chemotherapy. Journal of Cancer Research and Therapeutics. 2020;16(5):1173-1178. DOI: 10.4103/jcrt.JCRT_563_18.

2019 Yılı (3 Makale)

  1. Akdeniz N, Küçüköner M, Kaplan MA, Urakçı Z, Yerlikaya H, Karhan O, Teke F, Işıkdoğan A. Rare Occurrence of Synovial Sarcoma Originating from Dura Mater. Turkish Journal of Oncology. 2019;34(1):52-55. DOI: 10.5505/tjo.2019.1820.
  2. Akkuzu MZ, Küçüköner M, İrtegün Kandemir S, Akdeniz N, Urakçı Z, Kaplan MA, Büyükbayram H, Işıkdoğan A. Meme Kanserinde Brca-1 ve Brca-2’de Sık Görülen Polimorfizm Mutasyonların Bölgemizde Varlığı. Dicle Tıp Dergisi. 2019;46(3):478-485.
  3. Kaplan MA, Özaydın Ş, Yerlikaya H, Karaağaç M, Gümüş M, Çil T, Arslan ÜY, Özdemir N, Sakin A, Bilici M, vd. Clinicopathologic and Prognostic Differences between Three Different Age Groups (Child/Adolescent, Young Adults, and Adults) of Colorectal Cancer Patients: A Multicentre Study. Oncology Research and Treatment. 2019;42(10):519-528.

2018 Yılı (1 Makale)

  1. Oruç Z, Kaplan MA, Arslan Ç. An update on the currently available and future chemotherapy for treating bone metastases in breast cancer patients. Expert Opinion on Pharmacotherapy. 2018;19(14):1579-1590. DOI: 10.1080/14656566.2018.1504922.

Yılı Belirtilmemiş/Çoklu Girişler (2 Makale)

  1. Kaplan MA, Oruç Z, Gümüş M, Özaydın Ş, Elkıran ET, Dinç NŞ, Sakin A, Berk V, Akman T, Aytekin A, Yazılıtaş D, Dane F, İmamoğlu Gİ, Çubukçu E, Işıkdoğan A. The efficacy and reliability of sequential adjuvant anthracycline based chemotherapy and weekly paclitaxel regimen in human epidermal growth factor receptor 2 negative breast cancer: A retrospective analysis of a multicentre study. Journal of BUON. (Orijinal listedeki 55. ve 68. girişi temsil eder)
  2. Kalkan Z, Ebinç S, Urakçı Z, Oruç Z, İleri S, Tunç S, Küçüköner M, Kaplan MA, Işıkdoğan A. Evaluation of Immunotherapy and Targeted Therapies in the Treatment of Metastatic Malignant Melanoma. EURASIAN JOURNAL OF MEDICIAL INVESTIGATION. (Orijinal listedeki 47. ve 72. girişi temsil eder)

 

🔬 Akademik Yayınlar (Uzmanlık Alanlarına Göre Gruplandırılmış)

Akciğer Kanseri ve Mezotelyoma (16 Makale)

  • 2025
    • Akin Telli T, vd. Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group 2025. Clinical Lung Cancer.
    • Bozcuk HŞ, vd. Enhancing Treatment Decisions for Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations: A Reinforcement Learning Approach. Cancers.
    • Kalkan Z, vd. Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study. Medicina.
    • Şendur MAN, vd. Evaluation of implementation of evolving practice patterns in the first-line treatment of patients with metastatic non-small cell lung cancer in Turkiye (ESTIMATE). Future Oncology.
    • Urakçı Z, vd. Comparison of inflammatory indices in patients with metastatic non-small cell lung cancer. Revista da Associação Médica Brasileira.
  • 2024
    • Kahraman S, vd. Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases. Scientific Reports.
    • Karadurmuş N, vd. Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye. Current Medical Research and Opinion.
  • 2023
    • Ebinç S, vd. Prognostic factors and the prognostic role of inflammation indices in malignant pleural mesothelioma. Turkish Journal of Thoracic and Cardiovascular Surgery.
    • Ebinç S, vd. Neoadjuvant Therapy and Factors Influencing Survival in Locally Advanced Non-Small Cell Lung Cancer. Cureus.
    • Kaplan MA, vd. Established and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Group. Current Problems in Cancer.
    • Pirinççi E, vd. The relationship between inflammation markers, PET/CT parameters and disease prognosis in advanced non-small-cell lung cancer patients. Oncology in Clinical Practice.
    • Urakçı Z, vd. Efficacy of pemetrexed plus a platinum rechallenge in the treatment of pleural mesothelioma. Oncology in Clinical Practice.
  • 2022
    • Oruç Z, vd. A Low Body Fat Mass Ratio Predicts Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer. Nutrition and cancer.
    • Peters S, vd. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Annals of Oncology.

Meme Kanseri (8 Makale)

  • 2024
    • Urakçı Z, vd. Superiority of Pathologic Lymph Node Ratio over Positive Lymph Node Count in Operated Early-Stage Breast Cancer. Annali Italiani di Chirurgia.
  • 2023
    • Bilici A, vd. Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients. Acta Oncologica.
  • 2022
    • Akdeniz N, vd. The effect of exercise on disease-free survival and overall survival in patients with breast cancer. Irish Journal of Medical Science.
    • Bilici A, vd. Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Patients. Cancer Investigation.
    • Ebinç S, vd. Factors influencing HER2 discordance in nonmetastatic breast cancer and the role of neoadjuvant therapy. Future Oncology.
  • 2021
    • Akdeniz N, vd. The role of basal 18F-FDG PET/CT maximum standard uptake value and maximum standard uptake change in predicting pathological response in breast cancer patients. Nuclear Medicine Communications.
  • 2019
    • Kaplan MA, vd. The efficacy and reliability of sequential adjuvant anthracycline based chemotherapy and weekly paclitaxel regimen in HER2 negative breast cancer. Journal of BUON.
    • Akkuzu MZ, vd. Meme Kanserinde Brca-1 ve Brca-2’de Sık Görülen Polimorfizm Mutasyonların Bölgemizde Varlığı. Dicle Tıp Dergisi.
  • 2018
    • Oruç Z, vd. An update on the currently available and future chemotherapy for treating bone metastases in breast cancer patients. Expert Opinion on Pharmacotherapy.

Gastrointestinal ve Kolorektal Kanserler (7 Makale)

  • 2024
    • Özbay MF, vd. Sequential Use of Sorafenib and Regorafenib in Hepatocellular Cancer Recurrence After Liver Transplantation. Cancers.
    • Köstek O, vd. The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing. Journal of Chemotherapy.
  • 2023
    • Ebinç S, vd. PET/CT parameters for prediction of response to neoadjuvant therapy and prognosis in rectal cancer. Nuclear Medicine Communications.
    • Urakçı Z, vd. Comparison of Two Chemotherapy Regimens After First-Line Treatment for HER2-Negative Metastatic Gastric Cancer. Cureus.
  • 2022
    • Ebinç S, vd. Evaluation of Factors Predicting the Effectiveness of Regorafenib in the Treatment of Metastatic Colorectal Cancer. The Eurasian Journal of Medicine.
  • 2021
    • Akdeniz N, vd. The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer. International Journal of Colorectal Disease.
  • 2020
    • Tatlı AM, vd. A retrospective evaluation of geriatric patients with gastric cancer receiving systemic chemotherapy. Journal of Cancer Research and Therapeutics.
  • 2019
    • Kaplan MA, vd. Clinicopathologic and Prognostic Differences between Three Different Age Groups of Colorectal Cancer Patients. Oncology Research and Treatment.

Ürogenital Sistem Kanserleri (6 Makale)

  • 2024
    • Yıldırım HÇ, vd. Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma. Journal of Chemotherapy. (2 ayrı giriş)
  • 2023
    • Urakçı Z, vd. Factors predicting pathological complete response to neoadjuvant chemotherapy in patients diagnosed with non-metastatic muscle invasive urothelial bladder cancer. Northwestern Medical Journal.
    • Urakçı Z, vd. Effectiveness of Current First-Line Treatments and Evaluation of Prognostic Factors Related to Survival in Castration-Resistant Prostate Cancer with Isolated Bone Metastasis. Journal of Oncological Sciences.
  • 2022
    • Ebinç S, vd. Investigation of Factors Influencing the Prognosis in Prostate Cancer Patients with Isolated Bone Metastasis. Bulletin of Urooncology.
    • Ebinç S, vd. Evaluation of the effectiveness and tolerability of sunitinib and pazopanib in the first line treatment of metastatic renal cell carcinoma. Oncology in Clinical Practice.
    • İlhan Y, vd. Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer. International Journal of Gynecological Cancer.
  • 2021
    • Oruç Z, vd. Efficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastases. Future Oncology.

Diğer Nadir ve Hematolojik Kanserler (5 Makale)

  • 2023
    • Bilici A, vd. Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study. Cancer Chemotherapy and Pharmacology.
    • Ebinç S, vd. Factors influencing the prognosis in Braf wild-type metastatic malignant melanoma and the role of novel inflammation indices. Türkderm-Türk Deri Hastalıkları ve Frengi Arşivi.
  • 2022
    • Kalkan Z, vd. Evaluation of Immunotherapy and Targeted Therapies in the Treatment of Metastatic Malignant Melanoma. EURASIAN JOURNAL OF MEDICIAL INVESTIGATION.
  • 2021
    • Paydaş S, vd. Easier and more explanatory indices by integrating leukocyte lymphocyte ratio (LLR) and prognostic nutritional index (PNI) to IPS systems in cases with classical Hodgkin lymphoma. Leukemia Research.
  • 2020
    • Karaağaç M, vd. The real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: A retrospective cross-sectional study of a Turkish cohort. Journal of Oncology Pharmacy Practice.
  • 2019
    • Akdeniz N, vd. Rare Occurrence of Synovial Sarcoma Originating from Dura Mater. Turkish Journal of Oncology.

Genel Onkoloji ve COVID-19 (2 Makale)

  • 2024
    • Urakçı Z, vd. Causes of liver test abnormalities in newly diagnosed cancer patients and the investigation of etiological factors. Postgraduate Medicine.
  • 2021
    • Oruç Z, vd. Changes in medical oncology practice due to the COVID-19 pandemic in Turkey, and the risk of neglect of cancer patients. Dicle Tıp Dergisi.
    • Oruç Z, vd. COVID-19 infection in cancer patients: the effect of Hepatitis B immunization. Medical Research Journal.